65438+1On October 22nd, ICBC Credit Suisse Bank Fund and China Europe Fund successively disclosed the four quarterly reports of their funds for 20021year. The data shows that the management scale of Gulen has exceeded 100 billion yuan, reaching 1 10339 billion yuan. At the same time, the scale of Zhao Bei Frontier Medical Fund of ICBC also surged by 8.5 billion yuan in the fourth quarter.
In the fourth quarter of 2002/KLOC-0, Gulen increased his holdings of Pien Tze Huang and Jiuzhou Pharmaceutical, and Zhao Bei bought Mindray Medical and Changhong Technology. For the market outlook, the innovative pharmaceutical industry chain is still the most promising direction for the two medical women in the long run.
Glen was promoted to the level of 100 billion fund manager.
65438+1On October 22nd, five funds managed by "Medicine Goddess" Gü len published the fourth quarterly report of 20021.
By the end of 20021,the management scale of Gulen had exceeded100 billion yuan, reaching103.39 million yuan, an increase of13.38 million yuan compared with 9700438+0 million yuan in the previous quarter.
By the end of the third quarter of 2002/kloc-0, there were only two fund managers whose management scale exceeded 1000 billion, namely Liu Yanchun of Jing Shun Great Wall Fund and Zhang Kun of E Fund, whose management scales were 654.38+00261500 million yuan and 654.38+00 respectively. The latest quarterly report shows that Zhang Kun still maintains the management scale of 1000 billion yuan.
This also means that Gulen has officially become the third 100 billion-level fund manager among equity fund managers.
In the fourth quarter of 2002/kloc-0, the scale of the five funds managed by Gulen increased or decreased to varying degrees.
Among them, the scale of China-Europe medical and health fund reached 77.505 billion yuan, an increase of 654.38+04.065 billion yuan compared with the end of the third quarter, with a quarter-on-quarter increase of 22. 17%. The scale of medical innovation in China and Europe was 65.438+03.094 billion yuan, an increase of 65.438+047.6 million yuan from the end of the third quarter and an increase of 654.38+02.7% from the previous month. The scale of Alpha in Central Europe was 128. 1 1 100 million yuan, down 160 1 100 million yuan from the end of the third quarter and down 14.03% from the previous quarter. The scale of the new starting point of China-Europe Mingrui was 3.623 billion yuan, a decrease of 300 million yuan from the end of the third quarter and a decrease of 7.6% from the previous month. The selected scale of China-Europe research jointly managed by Shandong was 3.306 billion yuan, down 3.065438 billion yuan from the end of the third quarter and 8.3% from the previous quarter.
65438+1On October 22nd, the fourth quarter report of the fund 202 1 managed by Zhao Bei, the fund manager of ICBC Credit Suisse Bank, was also released. At the end of the fourth quarter of 2002/kloc-0, the scale of ICBC Frontier Medical Fund managed by Zhao Bei reached RMB2,265,438+24 million, an increase of RMB8,529 million compared with the end of the third quarter of 2002/kloc-0 and an increase of 62.77% from the previous quarter.
Although the scale has reached a new high, the net value of funds managed by Gulen and Zhao Bei has been declining in the fourth quarter of 2002/kloc-0. Wind data shows that in the fourth quarter, the net value of China Europe Medical Health A Fund decreased by 16. 14%, and that of ICBC Frontier Medical Fund decreased by 12.08%.
Glen and Zhao Bei represent the size and performance of the fund.
Medical women's stock positions have declined.
As well-known public medical fund managers, the fund stock positions of two female medical generals, Gulen and Zhao Bei, declined in the fourth quarter of 2002/KLOC-0.
Among them, the quarterly report of China-Europe Medical Health managed by Glen shows that as of the end of the fourth quarter of 20021.47%, the stock position of the fund was 8. 15 percentage points lower than that of the third quarter. According to the fourth quarterly report of ICBC Frontier Medical, managed by Zhao Bei, as of the end of the fourth quarter of 20021.32%, the stock position of the fund was 8 1.32%, which was 3.22 percentage points lower than that of the third quarter.
However, neither of them has changed much.
Glen said that in the fourth quarter of 200212002, the overall operation was maintained at a high level, and the leading enterprises in innovative pharmaceutical industry chain, medical services and high-quality generic drugs were laid out for a long time. At the end of the fourth quarter of 2002/kloc-0, the top ten medical and health stocks in China and Europe were Wuxi PharmaTech, Aier Ophthalmology, Gloria, Tiger Medicine, Kang Longhua, Mindray Medical, Pien Tze Huang, Tongce Medical, Boteng and Jiuzhou Pharmaceutical. Compared with the end of the third quarter of 200213, zhifei Bio and Medici have dropped out of their top ten positions, while Pien Tze Huang and Jiuzhou Pharmaceutical have newly joined the top ten positions.
Zhao Bei said that at the beginning of the fourth quarter of 200212002, he reduced his holdings of some second-tier CXO stocks with high valuation and increased his holdings of some stocks with low valuation and steady growth. Compared with the end of the third quarter, ICBC's frontier medical positions are still concentrated in innovative drugs and innovative drug industry chains, innovative medical devices, medical services, consumer medical care and other industries. The top ten leading medical institutions of ICBC are Wuxi PharmaTech, Gloria, Boteng, Mindray Medical, Tiger Medicine, Jiuzhou Pharmaceutical, Medici, Aier Ophthalmology, Roper Pharmaceutical and Changhong Technology. Compared with the end of the third quarter of 200213, Zhao Yanxin Medicine and Kanglong Chenghua dropped out of the top ten, while Mindray Medical and Changhong Technology rose to the top ten.
Continue to be optimistic about innovative drugs
At the same time, the two pharmaceutical fund managers are still optimistic about the direction of innovative pharmaceutical industry chain.
Glenn said that from the perspective of future configuration, the innovative pharmaceutical industry chain is still the most promising direction in the long run. From the top-level design of policies to the innovation accumulation of domestic enterprises in recent years, the domestic innovative pharmaceutical industry chain has been maintained at a high level for a long time. In addition, with the improvement of domestic residents' consumption power, knowledge structure and cognitive level, the popularity of products and services and residents' ability to pay are constantly improving, and leading enterprises in related industries also have long-term growth space.
In the fourth quarterly report, Zhao Bei pointed out that the pharmaceutical industry experienced a sharp adjustment in the fourth quarter, mainly because on the one hand, after the rise in 20021the first half of the year, the valuation was on the high side, and the decline of the biomedical sector in Hong Kong also triggered the market's enthusiasm for innovative drug research and development, which in turn triggered the adjustment of CXO-related stocks in the innovative drug industry chain; At the same time, the spread of the epidemic has also dragged down the prosperity of medical services and consumer medical care.
After this round of adjustment, she believes that the biomedical sector in Hong Kong has entered a relatively reasonable valuation stage, and the enthusiasm for investment and financing in the primary market has remained at a high level. In the future, innovative drugs and innovative drug industry chain may still maintain a high growth state. From the perspective of valuation cost performance, it has entered an attractive stage and is still strategically optimistic about this direction.